Hopp til innhold

Other news

A New Year Message from the CEO

Posted: 06/01/2026
LifeCare adobergb

As we enter a new year, I would like to take a moment to reflect on where Lifecare stands today – and, just as importantly, how we have arrived here.

Lifecare’s journey has never been about shortcuts. From the very beginning, our ambition has been to build a technology that works with natural biological principles rather than against them. Our sensor platform is inspired by the way living systems respond to glucose – not only at rest, but as part of dynamic physiological processes where molecules bind, water moves, and pressure shifts in response to everyday metabolic events. It is a quiet, fundamental logic – and one that demands patience, rigor, and respect.

That philosophy has shaped not only our technology, but also the way we develop our company.

From breakthrough to foundation
The past two years have marked a clear transition for Lifecare.

In 2024, we demonstrated our sensor technology in an implantable form — a milestone that confirmed the scientific foundation of our approach. In 2025, the task was different. The challenge was not to invent something new, but to translate that breakthrough into a robust, regulated, and repeatable product.

Throughout the year, we worked closely with experienced development and manufacturing partners to strengthen the full system: implant, electronics, communication, software, and processes. This work has been demanding, often incremental, and sometimes invisible from the outside – but it has been essential.

Step by step, Lifecare moved from a laboratory-driven concept to a product architecture designed to meet real-world requirements. End-to-end system performance has been refined. Longevity, readout stability, and robustness have been verified across relevant environments. Veterinary data has continued to support safety, biocompatibility, and functional reliability, while also contributing to a deeper understanding of how the system behaves under normal physiological variation.

Taken together, this work reflects a company that is no longer discussing a concept, but shaping a real medical device.

Why manufacturing repeatability matters
Shortly before Christmas, we announced an important manufacturing milestone: the successful production of a repeatable implant from a new batch under our updated production protocol.

For an implantable medical device, repeatability is not about volume or scale. It is about trust.

Trust that a device can be built consistently.
Trust that quality can be controlled and documented.
Trust that what is tested and validated is what can later be delivered.

This milestone did not stand alone. It was the result of a year of accumulated insight – from engineering, chemistry, materials, and process development – informed by growing experience with how the system performs across normal biological variation. These learnings are now reflected not only in the design of the implant, but in how it is manufactured. Achieving this level of reproducibility is a prerequisite for regulatory progress, clinical execution, and partner confidence.

It is also a clear signal of organizational maturity.

A year of consolidation
Looking back, 2025 was a year of consolidation for Lifecare.
We completed important organizational integration, strengthened our operational structure, and gathered our teams more closely around shared priorities. At the same time, we navigated periods of high pressure, particularly related to financing and execution sequencing – experiences that have reinforced the importance of clarity, discipline, and predictable communication as we move forward.

None of this diminishes the progress made. On the contrary, it has sharpened our focus on what truly matters as we approach the next phase.

Looking ahead: 2026 as a year of execution
Everything Lifecare has built over the past years – technology, infrastructure, competence, and partnerships – positions the company for a defining 2026.

The focus ahead is clear:

  • Disciplined regulatory execution, as we advance first-in-human activities and prepare for the next stages toward CE marking
  • Clinical progression, designed to further validate safety, performance, and reliability in a structured and compliant manner
  • Manufacturing and quality readiness, ensuring that reproducibility, documentation, and process control remain central
  • Commercial preparation, including the veterinary market, as a step toward early validation and learning
  • Capital efficiency, maintaining a clear link between investment, milestones, and risk reduction

Each of these priorities is aimed at the same objective: reducing uncertainty and building credibility – with regulators, partners, investors, and ultimately patients.

We are under no illusion that this path is easy. Medical technology development rarely is. But Lifecare enters the year with a stronger foundation than ever before, and with a clearer understanding of what execution at this level requires.

Ensuring financial capacity for execution
Following approval by the extraordinary general meeting, Lifecare will proceed with a rights issue with preferential subscription rights for existing shareholders. The subscription period will commence 7 January 2026.

The structure of the rights issue ensures equal treatment of existing shareholders and provides the opportunity to maintain relative ownership positions, in line with established market practice and prevailing market conditions.

Securing sufficient financial capacity is essential to support Lifecare’s execution priorities and to maintain focus on disciplined progress across regulatory, clinical, manufacturing, and commercial activities.

Confidence built on substance
As Lifecare approaches its 20th anniversary in 2026, it is worth reflecting on what kind of company we are building.

Progress rooted in natural principles may take time – but when it matures, it becomes robust, reliable, and transformative. That belief continues to guide us.

2024 gave us technological confirmation.
2025 gave us a product foundation and manufacturing discipline.
2026 is expected to bring further validation, credibility, and market readiness.

I want to thank our employees, partners, shareholders, and collaborators for their trust and commitment. The work behind us has been real, and the work ahead will be demanding – but it is precisely this combination that defines meaningful progress.

I look forward to the year ahead.

Joacim Holter
Chief Executive Officer
Lifecare ASA